CIK 0001574232 · Non-accelerated filer
Addex Therapeutics Ltd.
Sign in to watch- Ticker
- ADXN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- other
- Phone
- 01141228841555
- Business address
- CHEMIN DES MINES 9, GENEVA, Switzerland, CH-1202
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Lawton Vincent Michael Director | Grant or award · Stock-option (Right to Buy) | +942,854 | 1,444,452 | ||
| 2026-11-11 | Mills Roger CHIEF MEDICAL OFFICER | Grant or award · Stock-option (Right to Buy) | +942,854 | 992,854 | ||
| 2026-11-11 | Hill Raymond George Director | Grant or award · Stock-option (Right to Buy) | +942,854 | 1,215,961 | ||
| 2026-11-11 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +3,771,415 | 4,374,323 | ||
| 2026-11-11 | Nunn Jason Raleigh Director | Grant or award · Stock-option (Right to Buy) | +942,854 | 992,854 | ||
| 2026-11-11 | Manke Isaac Director | Grant or award · Stock-option (Right to Buy) | +942,854 | 992,854 | ||
| 2026-11-11 | Dyer Timothy Mark CHIEF EXECUTIVE OFFICER | Grant or award · Stock-option (Right to Buy) | +18,857,075 | 22,226,871 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −37,770 | 565,138 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +37,770 | 602,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −59,530 | 543,378 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +59,530 | 602,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −10,000 | 592,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +10,000 | 602,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −30,000 | 572,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +30,000 | 602,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −65,620 | 537,288 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +65,620 | 602,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −90,529 | 512,379 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Grant or award · Stock-option (Right to Buy) | +90,529 | 602,908 | ||
| 2026-09-02 | Teyssedou Lenaic Nathanael PRINCIPAL ACCOUNTING OFFICER | Returned to the company · Stock-option (Right to Buy) | −208,974 | 393,934 |
Page 1 of 3 · 51 trades